Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03526432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 30, 2026 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 2 months later Jun 30, 2026 → Aug 31, 2026
See other at-risk trials from University of Oklahoma

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 30, 2026 to Aug 31, 2026v20
  2. Primary completion date: Mar 31, 2026 to Jun 30, 2026v19
  3. Primary completion date: Aug 31, 2025 to Mar 31, 2026
    • Study completion date: Sep 2025 to Sep 2026
    v18
  4. Primary completion date: Feb 28, 2025 to Aug 31, 2025
    • Study completion date: May 2025 to Sep 2025
    v17
  5. Primary completion date: Aug 31, 2024 to Feb 28, 2025v16
Show 14 earlier versionsHide 14 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v15
  2. Trial status: Active, Not Recruiting to Recruitingv14 Show 4 more changesShow less
    • Enrollment target: 55 to 110
    • Primary completion date: Aug 31, 2023 to Aug 31, 2024
    • Study completion date: May 25, 2024 to May 2025
    • Site details revised at 3 of 3 sites
  3. Primary completion date: Aug 31, 2022 to Aug 31, 2023v13
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v12
  5. Primary completion date: Aug 31, 2021 to Aug 31, 2022
    • Study completion date: May 25, 2023 to May 25, 2024
    v11
  6. Primary completion date: May 25, 2021 to Aug 31, 2021v10
  7. Site details revised at 1 of 3 sitesv9
  8. Eligibility criteria expanded, about 244 wordsv8
  9. Site details revised at 1 of 3 sitesv7
  10. Study sites: 1 to 3
    • Eligibility criteria expanded, about 28 words
    v6
  11. Re-verified, no change to tracked fieldsv5
  12. Secondary endpoints: 3 to 4
    • Site contact updated
    v4
  13. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 1, 2018 to Aug 8, 2018
    • Site details revised
    v3
  14. Start date: May 25, 2018 to Aug 1, 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer. Safety and futility of this drug combination will be assessed to see what effect this treatment has on this patient population.
Trial Details
NCT Number NCT03526432
Lead Sponsor University of Oklahoma
Collaborators: Genentech, Inc.
Conditions
(from sponsor)		 Endometrial Cancer
Related terms Endometrial Neoplasms
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov